FLORBETAPIR, Placebo to match LY, Flortaucipir, Donanemab
I5T-MC-AACI
Phase 2 small_molecule active
Quick answer
FLORBETAPIR, Placebo to match LY, Flortaucipir, Donanemab for Alzheimer Disease is a Phase 2 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Alzheimer Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active